The controversial relationship between benign prostatic hyperplasia and prostate cancer: The role of inflammation

European Urology

Volumn 60, Issue 1, 2011, Pages 106-117

  De Nunzio, Cosimo ^a   Kramer, Gero ^b   Marberger, Michael ^b   Montironi, Rodolfo ^c   Nelson, William ^d   Schröder, Fritz ^e   Sciarra, Alessandro ^f   Tubaro, Andrea ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Benign prostatic hyperplasia; Chemokine; Immune; Inflammation; Prostate; Prostate cancer

Indexed keywords

ACETYLSALICYLIC ACID; CD19 ANTIBODY; CD20 ANTIBODY; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GLUTATHIONE TRANSFERASE P1; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D;

AUTOIMMUNITY; B LYMPHOCYTE; BACTERIAL INFECTION; CANCER IMMUNOTHERAPY; CARDIOVASCULAR DISEASE; CD3+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DIET; DISEASE ASSOCIATION; DISEASE COURSE; GENETIC PREDISPOSITION; HUMAN; MACROPHAGE; NONHUMAN; PATHOGENESIS; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; REVIEW; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VESICOURETERAL REFLUX;

HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS;

EID: 79957957222     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.03.055     Document Type: Review

References (79)

1. A. Alcaraz, P. Hammerer, A. Tubaro, F.H. Schröder, and R. Castro Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review Eur Urol 55 2009 864 875
2. A. Briganti, U. Capitanio, and N. Suardi Benign prostatic hyperplasia and its aetiologies Eur Urol Suppl 8 2009 865 871
3. A. Sciarra, F. Di Silverio, and S. Salciccia Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 52 2007 964 972 (Pubitemid 47332058)
4. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
5. G. Kramer, D. Mitteregger, and M. Marberger Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51 2007 1202 1216 (Pubitemid 46436310)
6. G. Robert, A. Descazeaud, Y. Allory, F. Vacherot, and A. de la Taille Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur Urol Suppl 8 2009 879 886
7. J.E. McNeal Normal histology of the prostate Am J Surg Pathol 12 1988 619 633
8. A. Bardia, E.A. Platz, S. Yegnasubramanian, A.M. De Marzo, and W.G. Nelson Anti-inflammatory drugs, antioxidants, and prostate cancer prevention Curr Opin Pharmacol 9 2009 419 426
9. A.M. De Marzo, E.A. Platz, and S. Sutcliffe Inflammation in prostate carcinogenesis Nat Rev Cancer 7 2007 256 269 (Pubitemid 46486616)
10. C.G. Drake Prostate cancer as a model for tumour immunotherapy Nat Rev Immunol 10 2010 580 593
11. D. Moore Inflammation of the prostate gland J Urol 38 1937 173 182
12. G. Kramer, G.E. Steiner, and A. Handisurya Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation Prostate 52 2002 43 58 (Pubitemid 34553191)
13. G. Kramer, and M. Marberger Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 16 2006 25 29 (Pubitemid 43041217)
14. G.E. Steiner, M.E. Newman, and D. Paikl Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate Prostate 56 2003 171 182 (Pubitemid 36918167)
15. G.E. Steiner, U. Stix, and A. Handisurya Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue Lab Invest 83 2003 1131 1146 (Pubitemid 37013048)
16. J.C. Nickel, C.G. Roehrborn, M.P. O'Leary, D.G. Bostwick, M.C. Somerville, and R.S. Rittmaster Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial J Urol 178 2007 896 900
17. J.C. Nickel, C.G. Roehrborn, M.P. O'Leary, D.G. Bostwick, M.C. Somerville, and R.S. Rittmaster The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial Eur Urol 54 2008 1379 1384
18. C.G. Roehrborn, S.A. Kaplan, and W.D. Noble The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study J Urol 173 2005 346
19. P.H.F. Schatteman, L. Hoekx, J.J. Wyndaele, W. Jeuris, and E. Van Marck Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density Eur Urol 37 2000 404 412 (Pubitemid 30157801)
20. J.C. Nickel Inflammation and benign prostatic hyperplasia Urol Clin North Am 35 2008 109 115 (Pubitemid 350166524)
21. F. Di Silverio, V. Gentile, and A. De Matteis Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis Eur Urol 43 2003 164 175 (Pubitemid 36221971)
22. J. Irani, P. Levillain, J.M. Goujon, D. Bon, B. Doré, and J. Aubert Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value J Urol 157 1997 1301 1303 (Pubitemid 27130803)
23. E. Di Carlo, S. Magnasco, T. D'Antuono, R. Tenaglia, and C. Sorrentino The prostate-associated lymphoid tissue (PALT) is linked to the expression of homing chemokines CXCL13 and CCL21 Prostate 67 2007 1070 1080 (Pubitemid 46983336)
24. G. Kramer, G.E. Steiner, P. Sokol, R. Mallone, G. Amann, and M. Marberger Loss of CD38 correlates with simultaneous upregulation of human leukocyte antigen-DR in benign prostatic glands, but not in fetal or androgen-ablated glands, and is strongly related to gland atrophy BJU Int 91 2003 409 416 (Pubitemid 36359652)
25. G. Robert, A. Descazeaud, and N. Nicolaiew Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis Prostate 69 2009 1774 1780
26. G. Theyer, G. Kramer, and I. Assmann Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia Lab Invest 66 1992 96 107
27. A.M. De Marzo, V.L. Marchi, J.I. Epstein, and W.G. Nelson Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis Am J Pathol 155 1999 1985 1992
28. G. Penna, B. Fibbi, and S. Amuchastegui Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation J Immunol 182 2009 4056 4064
29. G. Penna, B. Fibbi, M. Maggi, and L. Adorini Prostate autoimmunity: from experimental models to clinical counterparts Expert Rev Clin Immunol 5 2009 577 586
30. F. Martinon, V. Petrilli, A. Mayor, A. Tardivel, and J. Tschopp Gout-associated uric acid crystals activate the NALP3 inflammasome Nature 440 2006 237 241 (Pubitemid 43372104)
31. A. Sciarra, G. Mariotti, and S. Salciccia Prostate growth and inflammation J Steroid Biochem Mol Biol 108 2008 254 260 (Pubitemid 351179630)
32. C.B. Drachenberg, and J.C. Papadimitriou Prostatic corpora amylacea and crystalloids: similarities and differences on ultrastructural and histochemical studies J Submicrosc Cytol Pathol 28 1996 141 150 (Pubitemid 126439220)
33. B. Djavan, E. Eckersberger, and G. Espinosa Complex mechanisms in prostatic inflammatory response Eur Urol Suppl 8 2009 872 878
34. S. Gingras, R. Moriggl, B. Groner, and J. Simard Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13 Mol Endocrinol 13 1999 66 81 (Pubitemid 29022280)
35. A.D. Borowsky, K.H. Dingley, E. Ubick, K.W. Turteltaub, R.D. Cardiff, and R. Devere-White Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model Neoplasia 8 2006 708 715 (Pubitemid 44465522)
36. N.K. Narayanan, D. Nargi, L. Horton, B.S. Reddy, M.C. Bosland, and B.A. Narayanan Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib Prostate 69 2009 133 141
37. G. Bartsch, G. Daxenbichler, and H.P. Rohr Steroid pathophysiology of BPH. Correlative morphological and biochemical investigations on the stromal tissue of the human prostate J Steroid Biochem 19 1983 147 154 (Pubitemid 13049810)
38. H.P. Rohr, and G. Bartsch Human benign prostatic hyperplasia: a stromal disease? New perspectives by quantitative morphology Urology 16 1980 625 633 (Pubitemid 11197820)
39. L. Adorini, G. Penna, and S. Amuchastegui Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol) J Steroid Biochem Mol Biol 103 2007 689 693 (Pubitemid 46401347)
40. A. Handisurya, G.E. Steiner, and U. Stix Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate Prostate 49 2001 251 262 (Pubitemid 33117000)
41. H. Jähnisch, S. Fussel, and A. Kiessling Dendritic cell-based immunotherapy for prostate cancer Clin Dev Immunol 2010 2010 493 517
42. L. Wang, J.R. Yang, L.Y. Yang, and Z.T. Liu Chronic inflammation in benign prostatic hyperplasia: implications for therapy Med Hypotheses 70 2008 1021 1023 (Pubitemid 351400693)
43. C. Caruso, C.R. Balistreri, and G. Candore Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach Cancer Immunol Immunother 58 2009 1919 1933
44. P.R. Mangan, L.E. Harrington, and D.B. O'Quinn Transforming growth factor-beta induces development of the T(H)17 lineage Nature 441 2006 231 234
45. B. Oppmann, R. Lesley, and B. Blom Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 Immunity 13 2000 715 725
46. Descazeaud A, Weinbreck N, Robert G, et al. Transforming growth factor beta-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU Int. In press. DOI:10.1111/j.1464-410X.2010.09699.x.
47. A. Starsichova, E. Lincova, Z. Pernicova, A. Kozubík, and K. Soucek TGF-beta1 suppresses IL-6-induced STAT3 activation through regulation of Jak2 expression in prostate epithelial cells Cell Signal 22 2010 1734 1744
48. N.B. Delongchamps, G. de la Roza, and V. Chandan Evaluation of prostatitis in autopsied prostates - is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 179 2008 1736 1740
49. E.A. Klein, and R. Silverman Inflammation, infection, and prostate cancer Curr Opin Urol 18 2008 315 319 (Pubitemid 351489383)
50. W.G. Nelson, A.M. De Marzo, and W.B. Isaacs Prostate cancer N Engl J Med 349 2003 366 381 (Pubitemid 36886244)
51. S.J. Shook, J. Beuten, and K.C. Torkko Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans Clin Cancer Res 13 2007 5959 5964 (Pubitemid 47583924)
52. F.M. Wagenlehner, J.E. Elkahwaji, and F. Algaba The role of inflammation and infection in the pathogenesis of prostate carcinoma BJU Int 100 2007 733 737 (Pubitemid 47360188)
53. J.E. Nelson, and R.E. Harris Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study Oncol Rep 7 2000 169 170
54. R. Montironi, R. Mazzucchelli, and R. Pomante Immunohistochemical expression of pi class glutathione S-transferase in the basal cell layer of benign prostate tissue following chronic treatment with finasteride J Clin Pathol 52 1999 350 354 (Pubitemid 29200026)
55. X. Lin, K. Asgari, and M.J. Putzi Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide Cancer Res 61 2001 8611 8616 (Pubitemid 34013864)
56. K. Fujita, C.M. Ewing, R.H. Getzenberg, J.K. Parsons, W.B. Isaacs, and C.P. Pavlovich Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia Prostate 70 2010 473 481
57. J.E. Konig, T. Senge, E.P. Allhoff, and W. Konig Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer Prostate 58 2004 121 129 (Pubitemid 38160899)
58. F. Barbisan, R. Mazzucchelli, and A. Santinelli Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies Eur Urol 56 2009 105 112
59. G.S. Palapattu, S. Sutcliffe, and P.J. Bastian Prostate carcinogenesis and inflammation: emerging insights Carcinogenesis 26 2005 1170 1181 (Pubitemid 41417894)
60. D. Stock, P.A. Groome, and D.R. Siemens Inflammation and prostate cancer: a future target for prevention and therapy? Urol Clin North Am 35 2008 117 130 (Pubitemid 350176596)
61. F. Di Silverio, C. Bosman, and M. Salvatori Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) Eur Urol 47 2005 72 79 (Pubitemid 39575721)
62. D.S. Coffey Similarities of prostate and breast cancer: evolution, diet, and estrogens Urology 57 Suppl 1 2001 31 38
63. S. Rohrmann, W.G. Nelson, and N. Rifai Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans J Clin Endocrinol Metab 92 2007 2519 2525 (Pubitemid 47037352)
64. B.J. Deroo, and K.S. Korach Estrogen receptors and human disease J Clin Invest 116 2006 561 570 (Pubitemid 43326860)
65. M.C. Bosland Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis Ann N Y Acad Sci 1089 2006 168 176 (Pubitemid 47092095)
66. G.S. Prins, and K.S. Korach The role of estrogens and estrogen receptors in normal prostate growth and disease Steroids 73 2008 233 244
67. A.W. Hsing, L.C. Sakoda, and S. Chua Jr. Obesity, metabolic syndrome, and prostate cancer Am J Clin Nutr 86 2007 843 857
68. C. Murphy, M. McGurk, and J. Pettigrew Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer Clin Cancer Res 11 2005 4117 4127 (Pubitemid 40791576)
69. R. Vela Navarrete, J.V. Garcia Cardoso, A. Barat, F. Manzarbeitia, and A. López Farré BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay Eur Urol 44 2003 549 555 (Pubitemid 37328630)
70. F.K. Habib Serenoa repens: the scientific basis for the treatment of benign prostatic hyperplasia Eur Urol Suppl 8 2009 887 893
71. F. Vacherot, M. Azzouz, and S. Gil-Diez-de-Medina Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia Prostate 45 2000 259 266
72. ®) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies Eur Urol 33 1998 340 347 (Pubitemid 28140436)
73. F.C. Lowe The role of Serenoa repens in the clinical management of lower urinary tract symptoms due to benign prostatic hyperplasia Eur Urol Suppl 8 2009 894 897
74. E.J. Jacobs, C. Rodriguez, and A.M. Mondul A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence J Natl Cancer Inst 97 2005 975 980 (Pubitemid 41430563)
75. R.S. Pruthi, J.E. Derksen, and D. Moore A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy BJU Int 93 2004 275 278 (Pubitemid 38253569)
76. F. Di Silverio, A. Sciarra, and V. Gentile Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy Urology 71 2008 947 951
77. P.W. Kantoff, C.S. Higano, and N.D. Shore IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
78. G. Penna, N. Mondaini, and S. Amuchastegui Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia Eur Urol 51 2007 524 533 (Pubitemid 44937795)
79. A. Sciarra, V. Panebianco, and M. Ciccariello Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer Cancer Invest 28 2010 424 432